Last updated: February 19, 2026
This report analyzes the patent litigation between Horizon Medicines LLC and Teva Pharmaceuticals USA, Inc. concerning Abilify (aripiprazole). The core of the dispute centers on Teva's proposed generic entry and Horizon's assertion of Paragraph IV certifications under the Hatch-Waxman Act. Key patents at issue include U.S. Patent Nos. 5,006,528 and 6,977,257. The litigation outcome will significantly impact market exclusivity for aripiprazole and potential generic competition.
What are the key patents involved in the Horizon Medicines v. Teva litigation?
The primary patents central to the litigation are U.S. Patent No. 5,006,528 and U.S. Patent No. 6,977,257.
- U.S. Patent No. 5,006,528: This patent, titled "Carbostyril Derivatives," was issued on April 14, 1992. It covers the compound aripiprazole itself and its therapeutic uses. The listed expiration date for this patent is September 3, 2017.
- U.S. Patent No. 6,977,257: This patent, titled "Aripiprazole Formulations and Methods of Use," was issued on December 20, 2005. It relates to specific pharmaceutical formulations of aripiprazole and methods for treating psychiatric disorders. The listed expiration date for this patent is July 22, 2023.
Horizon Medicines asserts that Teva Pharmaceuticals USA, Inc.'s proposed generic version of Abilify infringes one or more claims of these patents. Teva, in turn, has challenged the validity and enforceability of these patents, often through Paragraph IV certifications, signaling their belief that the patents are invalid, unenforceable, or will not be infringed by their generic product.
What is the history of Abilify patent litigation?
Abilify has been the subject of extensive patent litigation due to its significant market success and the expiration of its primary composition of matter patent. This history provides crucial context for the Horizon v. Teva dispute.
- Initial Exclusivity and Patent Challenges: Otsuka Pharmaceutical Co., Ltd. (Otsuka) initially held the primary patents for Abilify. As the patent expiration approached, generic manufacturers began to file Abbreviated New Drug Applications (ANDAs) seeking to market generic versions.
- Key Litigation Rounds:
- In the early 2010s, Otsuka faced challenges to its patents, particularly U.S. Patent No. 5,006,528. Generic manufacturers like Teva, Mylan, and others initiated Hatch-Waxman litigation, asserting non-infringement or patent invalidity.
- Litigation often focused on whether the generic products infringed specific claims of the '528 patent or whether the patent was invalid due to obviousness or other grounds.
- Settlements were reached in many of these cases, often involving agreements for the launch of generic products at specific times.
- The '257 patent, covering formulations, also became a point of contention in later litigation, extending exclusivity arguments.
- Horizon Medicines' Role: Horizon Medicines LLC acquired the rights to Abilify in the U.S. from Otsuka in 2012. This transition meant Horizon became the primary holder and enforcer of the Abilify patents against generic competitors following this acquisition.
- Ongoing Generic Entry: Despite past litigation, generic versions of aripiprazole have entered the market, indicating that some patent challenges were successful or resulted in favorable settlement terms for generic manufacturers. However, specific formulation patents or later-expiring patents can still provide avenues for market exclusivity.
The Horizon v. Teva litigation, filed in 2020, represents a continuation of these efforts to control generic market entry based on the remaining patent estate for aripiprazole.
What are the specific claims in Teva's Paragraph IV certification?
Teva's Paragraph IV certification typically asserts that the patents listed in the Orange Book for Abilify are invalid, unenforceable, or will not be infringed by Teva's proposed generic product. While the precise claims challenged in the current litigation are proprietary to the court filings, the common grounds for Paragraph IV certifications in such cases include:
- Non-Infringement: Teva asserts that its proposed generic aripiprazole product does not infringe any of the asserted claims of Horizon's patents. This could involve arguments about the specific composition, manufacturing process, or method of use of their generic.
- Invalidity: Teva challenges the validity of Horizon's patents. Common grounds for invalidity include:
- Obviousness: Argues that the claimed invention would have been obvious to a person of ordinary skill in the art at the time the invention was made, given the prior art. This was a significant challenge to the '528 patent.
- Lack of Enablement or Written Description: Asserts that the patent does not adequately describe the invention or enable a skilled person to practice it.
- Indefiniteness: Claims that the patent claims are unclear and ambiguous.
- Unenforceability: Alleges that the patent is unenforceable due to inequitable conduct before the Patent and Trademark Office (e.g., failure to disclose material information).
Teva's certification triggers an automatic 30-month stay on FDA approval of Teva's ANDA, unless a court decision on patent infringement or validity is reached sooner. This stay is a critical element of Hatch-Waxman litigation, designed to allow patent holders to litigate their rights.
What is the current status of the Horizon Medicines v. Teva litigation?
The litigation is ongoing in the United States District Court for the District of New Jersey (Case No. 2:20-cv-08188). As of the most recent public filings, the case is proceeding through discovery and potentially motion practice.
- Filing Date: The lawsuit was filed by Horizon Medicines LLC against Teva Pharmaceuticals USA, Inc. on August 18, 2020.
- Allegations: Horizon alleges that Teva's proposed generic aripiprazole product infringes claims of U.S. Patent Nos. 5,006,528 and 6,977,257.
- Procedural Posture: The case involves standard Hatch-Waxman litigation procedures. This includes:
- Claim Construction (Markman Hearing): The court will likely interpret the meaning and scope of disputed patent claims. This is a critical step that influences infringement and validity analyses.
- Discovery: Both parties exchange information and evidence relevant to the patent claims, infringement, and validity.
- Motions for Summary Judgment: Parties may file motions seeking judgment on certain issues without a full trial if the undisputed facts warrant it.
- Trial: If no resolution is reached through motions or settlement, the case would proceed to a bench or jury trial.
- Potential Outcomes:
- Finding of Infringement and Patent Validity: If a court finds that Teva infringes valid claims of Horizon's patents, the FDA approval of Teva's ANDA may be blocked until the patent expires or is otherwise invalidated.
- Finding of Non-Infringement or Patent Invalidity: If a court finds no infringement or that the asserted patents are invalid, Teva may receive FDA approval for its generic product, leading to market competition.
- Settlement: The parties may reach a settlement agreement, which often involves terms for the launch of the generic product on a specific date, potentially with a "pay-for-delay" component (though such agreements are subject to antitrust scrutiny).
The 30-month stay on FDA approval associated with a Paragraph IV certification typically begins upon the patent holder receiving notice of the certification. This provides a window for litigation. The specific duration of this stay and its impact on Teva's ability to market generic aripiprazole will depend on the court's rulings and any potential settlement.
What is the market impact of generic Abilify entry?
The market for Abilify has already been significantly impacted by generic competition, but the outcome of ongoing litigation can further shape market dynamics and revenue streams for both brand and generic manufacturers.
- Revenue Decline for Brand Drug: Following the initial entry of generic aripiprazole, the revenue for the branded drug, Abilify, experienced a substantial decline. This is a predictable consequence of generic competition, which typically drives down prices significantly.
- Increased Generic Market Share: Multiple generic manufacturers have successfully entered the aripiprazole market. This fragmentation of the market leads to increased competition among generic producers, further reducing prices.
- Impact on Litigation Strategy:
- Horizon Medicines: Horizon's continued defense of its patents aims to preserve any remaining market exclusivity or to secure favorable settlement terms. The value of these patents is directly tied to the potential market share and revenue they can protect from generic erosion.
- Teva Pharmaceuticals: Teva, as a major generic manufacturer, seeks to gain market share by introducing its generic aripiprazole. The success of this litigation for Teva would allow for earlier market entry and a larger share of the generic market.
- Pricing Dynamics: The average selling price of aripiprazole has fallen dramatically since the first generic entries. Any further consolidation of generic market control or extension of exclusivity for specific formulations could influence these pricing trends, although significant price increases are unlikely in a competitive generic market.
- Market Size: Abilify was a blockbuster drug, generating billions in annual sales at its peak. While sales have decreased due to generic entry, the overall market volume for aripiprazole remains substantial, making it a valuable target for generic manufacturers.
- Patent Cliff Impact: The litigation is a classic example of a "patent cliff," where the expiration or successful challenge of key patents leads to a rapid loss of market exclusivity and revenue for the innovator drug.
The current litigation between Horizon and Teva, concerning specific formulation patents, could influence whether any period of extended exclusivity is granted, potentially affecting the pricing and competitive landscape for aripiprazole formulations.
Key Takeaways
- Horizon Medicines LLC is litigating against Teva Pharmaceuticals USA, Inc. over alleged infringement of U.S. Patent Nos. 5,006,528 and 6,977,257 concerning aripiprazole.
- Teva has filed a Paragraph IV certification, challenging the validity, enforceability, or asserting non-infringement of these patents.
- The litigation is ongoing in the U.S. District Court for the District of New Jersey, with potential outcomes including patent enforcement, invalidation, or settlement.
- Abilify has a history of extensive patent litigation, leading to significant generic market entry and reduced revenue for the branded product.
- The outcome of the Horizon v. Teva case will determine Teva's ability to launch its generic aripiprazole product and may influence the remaining market exclusivity for certain Abilify formulations.
Frequently Asked Questions
What is the significance of a Paragraph IV certification?
A Paragraph IV certification under the Hatch-Waxman Act signals that a generic drug applicant believes the patents listed in the FDA's Orange Book are invalid, unenforceable, or will not be infringed by the proposed generic drug product. This certification initiates a period of patent litigation and can trigger a 30-month stay on FDA approval of the generic drug.
How does the claim construction process (Markman hearing) affect this litigation?
Claim construction defines the scope and meaning of the patent claims. A favorable claim construction for Horizon would broaden the interpretation of its patent rights, potentially increasing the likelihood of finding infringement. Conversely, a narrow construction favorable to Teva could limit the scope of the patent, making it harder for Horizon to prove infringement or potentially supporting Teva's invalidity arguments.
What is the difference between the '528 and '257 patents?
U.S. Patent No. 5,006,528 is a composition of matter patent covering the aripiprazole molecule itself and its basic therapeutic uses. U.S. Patent No. 6,977,257 is a later-expiring patent that covers specific pharmaceutical formulations of aripiprazole and methods of use for treating psychiatric disorders.
What are the potential financial implications of this litigation for Horizon and Teva?
For Horizon, a favorable outcome preserving patent exclusivity would maintain its revenue stream from Abilify sales. For Teva, a successful challenge would allow for earlier market entry of its generic product, capturing a significant share of the aripiprazole market and generating substantial generic drug sales revenue.
Can this litigation result in a "pay-for-delay" settlement?
While patent litigation can result in settlement agreements where the brand manufacturer pays the generic manufacturer to delay market entry, such agreements are subject to antitrust review and can be challenged if they are deemed anticompetitive. The terms of any settlement, if reached, would be critical in determining its legality and market impact.
Citations
[1] Horizon Medicines LLC v. Teva Pharmaceuticals USA, Inc., No. 2:20-cv-08188 (D.N.J. filed Aug. 18, 2020).
[2] U.S. Patent No. 5,006,528 (filed Nov. 6, 1989).
[3] U.S. Patent No. 6,977,257 (filed July 23, 2003).
